A monoclonal antibody against nodular dermatosis virus and its application

By optimizing the LSDV P32 protein and E. coli expression system, monoclonal antibodies were prepared, combined with inactivated goat pox virus, the biosafety hazards and complexity of nodular skin disease virus antibody detection was solved, and efficient and safe antibody detection was achieved and vaccine efficacy assessment.

CN115260298BActive Publication Date: 2024-11-19CHINA INST OF VETERINARY DRUG CONTROL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202210428603.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-22
Publication Date
2024-11-19
Estimated Expiration
2042-04-22

AI Technical Summary

Technical Problem

Nodular skin disease virus (LSDV) lacks special treatment and commercial vaccines. The existing antibody detection methods have biosafety risks and complexity, making it difficult to effectively screen antibody-negative animals and evaluate the effectiveness of the vaccine.

Method used

By optimizing the coding sequence of the LSDV P32 protein, a recombinant expression system was constructed to obtain the soluble truncated protein rLP32Δ, and monoclonal antibodies were prepared using the E. coli expression system, combining inactivated goat poxvirus as an immunogen, and screening and establishing the LSDV antibody blocking ELISA detection method .

Benefits of technology

It realizes efficient, safe and simple LSDV antibody detection, reduces biosafety risks, supports vaccine research and development and efficacy testing, and provides fast, sensitive and specific detection methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115260298B_ABST
    Figure CN115260298B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of medical technology, and specifically to a monoclonal antibody against nodular dermatosis virus and its application. The present invention provides an immunogenic protein rLP32Δ, the coding sequence of which is shown in positions 4 to 717 of SEQ ID No.1; the amino acid sequence of which is shown in positions 2 to 239 of SEQ ID No.2. The present invention uses inactivated goat pox virus as an immunogen to immunize mice, and obtains a truncated protein rLP32Δ of the P32 protein with strong immunogenicity of LSDV through a prokaryotic system, and uses rLP32Δ to screen LSDV monoclonal antibody hybridoma cell lines and establish a subsequent ELISA detection method, thereby maintaining the natural conformation of the viral antigen to the greatest extent while greatly avoiding unnecessary biosafety risks.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a monoclonal antibody against nodular dermatosis virus and an application thereof. Background Art

[0002] Lumpy skin disease (LSD) is an exotic disease caused by the Lumpy Skin Disease Virus (LSDV), which can cause high mortality (40-75%) in young cattle and clinical symptoms such as decreased milk production, abortion, and decreased beef production in dairy cows, resulting in serious economic losses. LSD was first reported in sub-Saharan Africa in 1929, and then the infection of LSD spread rapidly, first to most parts of Africa, then through the Middle East, and further to Europe and the Asian part of Eurasia. Since 2016, LSD outbreaks have occurred in many countries in Southwest Asia and Eastern Europe, such as Turkey, Greece, Bulgaria, the Republic of North Macedonia, Serbia, followed by several new countries in East Asia, including China, Bangladesh, and India.

[0003] There is currently no specific treatment for LSD, and there is no commercial vaccine for nodular dermatosis in my country. The nodular dermatosis virus (LSDV) is an imported virus, belonging to the second category of animal epidemic diseases and the first category of management. That is, the study of the virus requires specific laboratory conditions, which creates obstacles to the study of the virus.

[0004] Existing studies have shown that LSDV belongs to the Poxviridae family and the Cappoxvirus genus (CapPVs) along with SPPV and GTPV. LSDV is a relatively large double-stranded DNA enveloped virus with a genome of approximately 151 kbp, containing 156 predicted genes, and has 97% homology with the genomes of the other two Cappoxvirus genus, SPPV and GTPV, resulting in cross-protection between LSDV and Cappox.

[0005] Therefore, the current research direction of vaccines in my country mainly uses inactivated goat pox virus vaccine to prevent nodular dermatosis in cattle. However, since LSD is a new foreign disease in my country, my country currently controls the disease as a Class II animal disease. Infected cattle should be killed and disposed of harmlessly according to requirements. In addition, there is a lack of effective LSDV antibody detection kits, which makes it difficult to screen LSDV antibody-negative animals during the development of related vaccines. In addition, the immune effect evaluation of target animals can only be carried out by using an immune attack method involving active LSDV, which poses a great biosafety risk. Therefore, it is urgent to establish a rapid, sensitive, and specific LSDV antibody ELISA detection method.

[0006] The prior art has disclosed the P32 protein of the Lumpy Skin Disease Virus LSDV and its antigenicity, but the obtained P32 protein is highly hydrophobic, which affects its biological application. The P32 protein obtained by the prior art mostly exists in the form of inclusion bodies, with a small amount of soluble protein, and the processing process of the expression product is complicated, and the expression amount is also low. Summary of the invention

[0007] The purpose of the present invention is to provide a recombinant soluble truncated protein rLP32Δ of the P32 protein of LSDV, and to provide a hybridoma cell line that secretes anti-LSDV, and to use the hybridoma cell line to prepare monoclonal antibodies, and further establish a blocking ELISA detection method for LSDV, thereby providing technical support for the development of LSDV vaccines and the development of alternative methods for efficacy testing.

[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows.

[0009] In a first aspect, the present invention provides an immunogenic protein rLP32Δ, wherein the coding sequence of the rLP32Δ is shown in positions 4 to 717 of SEQ ID No.1.

[0010] In a specific embodiment, the coding sequence is optimized according to the preferred codons of Escherichia coli for the amino acid coding sequence of the P32 protein of LSDV at positions 1 to 238, and a 6×His tag is introduced at the C-terminus to synthesize the gene fragment GLP32Δ.

[0011] Furthermore, the amino acid sequence of the protein rLP32Δ is shown in positions 2 to 239 of SEQ ID No.2.

[0012] In a specific embodiment, it is prepared using the BL21 (DE3) cell strain of the host cell Escherichia coli that recombinantly expresses rLP32Δ as a production strain;

[0013] The strain is Escherichia coli BL / 321 strain, and its preservation number is CGMCC No.24528.

[0014] Furthermore, the protein rLP32Δ is a soluble protein.

[0015] In a specific embodiment, the soluble rLP32Δ protein is obtained by fermentation culture, induced expression, bacterial cell disruption, and separation and purification of the soluble antigen protein using the production strain Escherichia coli BL / 321.

[0016] In a second aspect, the present invention provides a hybridoma cell line that secretes anti-LSDV monoclonal antibodies.

[0017] A hybridoma cell line secreting anti-LSDV monoclonal antibodies, wherein the hybridoma cell line is LSDV hybridoma cell CP4E2;

[0018] Its accession number is CGMCC No.45131.

[0019] In a specific embodiment, the hybridoma cell line is prepared by the following method:

[0020] S101 goatpox virus was used as an antigen to immunize animals, and the spleen cells of the immunized animals were fused with SP2 / 0 cells;

[0021] S102 fusion cells were used to screen positive clones and subclones using the recombinant protein rLP32Δ, and the hybridoma cell line that could stably secrete anti-LSDV monoclonal antibodies was the LSDV hybridoma cell line CP4E2.

[0022] In a third aspect, the present invention provides a monoclonal antibody against LSDV.

[0023] A monoclonal antibody to LSDV, wherein the monoclonal antibody is secreted by LSDV hybridoma cell CP4E2:

[0024] The monoclonal antibody is monoclonal antibody 4E2.

[0025] In a specific embodiment, the monoclonal antibody 4E2 is obtained from the culture medium of LSDV hybridoma cell CP4E2 or by inoculating the hybridoma cell line into the peritoneal cavity of mice to produce ascites.

[0026] In a specific embodiment, the monoclonal antibody 4E2 is obtained by inoculating the hybridoma cell line CP4E2 into the peritoneal cavity of mice to produce ascites.

[0027] In a fourth aspect, the present invention provides a method for preparing an anti-LSDV polyclonal antibody.

[0028] A method for preparing anti-LSDV polyclonal antibodies comprises the following steps: injecting cattle with LSDV subcutaneously at multiple points in the abdomen, collecting serum from the diseased cattle 14 days after the infection, and separating the LSDV polyclonal antibodies from the serum.

[0029] In a fifth aspect, the present invention provides a use of a monoclonal antibody against LSDV.

[0030] A use of a monoclonal antibody of LSDV for preparing a medicament, a reagent, a test plate or a test kit;

[0031] The reagent, detection plate or kit is used to detect LSDV in a sample;

[0032] The medicament is used for screening LSDV antibody-negative animals and / or testing vaccine efficacy.

[0033] The preparation of monoclonal antibodies is the basis for establishing an excellent ELISA detection method, and the immunogen is the key to the preparation of monoclonal antibodies. To this end, the present invention uses inactivated goat pox virus as an immunogen to immunize mice, and obtains the truncated protein rLP32Δ of the P32 protein with strong immunogenicity of LSDV through a prokaryotic system, and uses rLP32Δ to screen LSDV monoclonal antibody hybridoma cell lines and establish subsequent ELISA detection methods, thereby maintaining the natural conformation of the viral antigen to the greatest extent and greatly avoiding unnecessary biosafety risks.

[0034] At the same time, the present invention uses the screened monoclonal antibodies to establish a blocking ELISA detection method for LSDV antibodies, thereby providing technical support for the research of LSDV-related vaccines and the development of alternative methods for efficacy testing.

[0035] The present invention is the first to obtain the LSDV truncated recombinant P32 protein rLP32Δ expressed in a soluble form through an E. coli expression system, and for the first time to use the protein as a coating antigen and inactivated goat pox virus as an immune antigen to screen anti-monoclonal antibody hybridoma cell lines and establish LSDV antibody blocking ELISA. The technical solution of the present invention has the following advantages:

[0036] (1) For the first time, through codon optimization and artificial synthesis technology, the soluble expression of LSDV recombinant protein rLP32Δ was achieved through the Escherichia coli expression system, thus avoiding the complexity of inclusion body protein purification.

[0037] (2) For the first time, an exogenous expression system was used to obtain the recombinant protein of LSDV and inactivated goat pox virus to prepare monoclonal antibodies, which can reduce the biosafety risks of LSDV.

[0038] (3) For the first time, rLP32Δ with a purity of more than 90% was used as the coating antigen to establish LSDV antibody blocking ELISA, which not only ensured the purity of the coating antigen but also solved the safety hazard of LSDV.

[0039] The present invention obtains for the first time a hybridoma cell strain secreting anti-LSDV monoclonal antibodies, the hybridoma cell strain can stably and efficiently secrete anti-LSDV monoclonal antibodies, and can realize large-scale batch production.

[0040] The present invention is the first to establish an antibody blocking ELISA detection method for LSDV using anti-LSDV monoclonal antibodies. The method also has the characteristics of simple sample operation, low cost, rapid reaction, and strong specificity, thereby providing a basis for the screening of LSDV antibody-negative animals and the research on alternative methods for related vaccine efficacy testing.

[0041] Cell preservation:

[0042] The Escherichia coli BL / 321 strain and the LSDV hybridoma cell CP4E2 strain provided by the present invention are obtained by the inventor of the present invention by self-screening and are deposited in the General Microbiology Center of the China National Committee for the Preservation of Microorganisms. The Escherichia coli BL / 321 strain and the LSDV hybridoma cell CP4E2 strain are deposited as: Escherichia coli, mouse hybridoma cells, and the deposit numbers are CGMCCNo.24528 and CGMCCNo.45131. The deposit date is March 14, 2022, and the depository is the General Microbiology Center of the China National Committee for the Preservation of Microorganisms. The depository address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The Escherichia coli BL / 321 strain and the LSDV hybridoma cell CP4E2 strain were identified as alive by the General Microbiology Center of the China National Committee for the Preservation of Microorganisms on March 14, 2022. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 The results show the identification of soluble expression of rLP32Δ.

[0044] Figure 2 The figure shows the SDS-PAGE identification result of rLP32Δ purification.

[0045] Figure 3 This is the result of identifying the purification effect of monoclonal antibody 4E2.

[0046] Figure 1 In the figure, 1 is the cell lysate of uninduced cells; 2 is the cell lysate induced at 15℃ and 16h; 3 is the cell lysate induced at 37℃ and 4h; 4 is the supernatant of cell lysis of uninduced cells; 5 is the supernatant of cell lysis induced at 15℃ and 16h; 6 is the supernatant of cell lysis induced at 37℃ and 4h; 7 is the precipitate of cell lysis of uninduced cells; 8 is the precipitate of cell lysis induced at 15℃ and 16h; 9 is the precipitate of cell lysis induced at 37℃ and 4h.

[0047] Figure 2 In the figure, M is Protein marker; 1 is BSA (1 μg); 2 is purified rLP32Δ protein.

[0048] Figure 3In the figure, M is a protein marker; 1 is the purified monoclonal antibody 4E2. DETAILED DESCRIPTION

[0049] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail in the following examples. The following examples are only used to illustrate the invention but are not used to limit the scope of the present invention.

[0050] Example 1

[0051] Preparation of rLP32Δ protein

[0052] 1. Construction of rLP32Δ expression vector

[0053] (1) Gene synthesis

[0054] The amino acid coding sequence of the 1st to 238th positions of the LSDV (Genbank: AAK85035.1) P32 protein was optimized according to the preferred codons of Escherichia coli, and a 6×His tag was introduced at the C-terminus. The gene fragment GLP32Δ was artificially synthesized by chemical synthesis, which contained a total of 744 nucleotides. The specific nucleic acid sequence is shown in SEQ ID No.1; the specific amino acid sequence is shown in SEQ ID No.2.

[0055] (2) Construction of fusion expression vector

[0056] The synthetic GLP32Δ gene was used as a template and primer pair 1F / 1R was used for PCR amplification.

[0057] The sequence of the upstream primer 1F is:

[0058] 5'-cggccatatg gcagatattc c-3';

[0059] The restriction endonuclease Nde I site and protective bases were introduced into the 5' end.

[0060] The sequence of downstream primer 1R is:

[0061] 5'-ccgcaagcttttagtggtga tg-3';

[0062] A restriction endonuclease Hind III site and protective bases were introduced into the 5' end.

[0063] The PCR system is: Buffer(Mg 2+ plus) 10 μL, dNTPs 4 μL, upstream and downstream primers 1 μL each, 1 μL polymerase, 2 μL DNA template, add dd H2O to 50 μL system.

[0064] The PCR reaction conditions were as follows: pre-denaturation at 98°C for 1 min; denaturation at 98°C for 10 s, annealing at 56°C for 30 s, extension at 72°C for 1 min, for a total of 33 cycles; and final loop extension at 72°C for 10 min.

[0065] After the amplified target DNA band was recovered, it was digested with Nde I / Hind III double enzymes and ligated with the pET30a vector that had been digested with the same enzymes to obtain the GLP32Δ gene-inserted positive clone pET30a-GLP32Δ. The obtained prokaryotic expression plasmid pET30a-GLP32Δ was transformed into DH5α competent cells, and a single clone was picked out and placed in LB liquid culture medium containing kanamycin. It was cultured at 37°C with shaking overnight, and the plasmid was extracted for later use.

[0066] 2. Expression and purification of rLP32Δ

[0067] (1) Construction of genetically engineered strains carrying the recombinant GLP32Δ gene

[0068] The extracted plasmid was transformed into Escherichia coli BL21 (DE3) competent cells, and a single clone was picked and placed in LB liquid medium containing kanamycin. It was cultured at 37°C with shaking overnight. After PCR identification, it was named Escherichia coli BL / LP32Δ strain after containing the target DNA fragment. An equal volume of 50% glycerol LB was added and frozen at -70°C.

[0069] (2) Expression and purification of rLP32Δ

[0070] The recombinant Escherichia coli (E. coli) BL / LP32Δ strain was inoculated into 1 L LB liquid medium containing kanamycin for fermentation and cultured at 37°C with shaking at OD 600 When the pH value was 0.6-0.8, IPTG solution with a final concentration of 0.5 mM was added to induce the culture for 4 hours. After the culture was completed, the cells were collected by centrifugation, and 10 mL of lysis solution [0.02 mol / L Tris buffer (pH 7.2), 0.3 mol / L NaCl] was added per gram of cell weight to resuspend the cells. The cells were ultrasonically disrupted in an ice water bath for 30 minutes. The disruption conditions were: working for 9 seconds, resting for 9 seconds, and the ultrasonic power was 400 W. The soluble expression was identified as follows: Figure 1 shown.

[0071] The disrupted bacterial solution was centrifuged at 4°C and 12,000 r / min for 10 min, and the supernatant was collected. The soluble target protein in the bacterial lysis supernatant was purified according to the instruction manual of the Ni-IDA affinity chromatography medium kit (Nanjing GenScript Co., Ltd.) and filtered through a 0.22 μm pore size filter membrane to obtain the initially purified target protein rLP32Δ. The SDS-PAGE identification results of the purified rLP32Δ are shown in Figure 2. Figure 2 shown.

[0072] Example 2

[0073] Screening of hybridoma cell lines secreting monoclonal antibodies against P32 protein of leukemia virus and preparation of monoclonal antibody ascites

[0074] 1. Immunization of BALB / c mice and determination of antibody titers

[0075] Three BALB / c mice aged 6 to 8 weeks were immunized with inactivated goat pox virus as the immunization antigen for a total of four immunizations, with an interval of 2 weeks between each immunization.

[0076] For the first immunization, add an equal volume of Freund's complete adjuvant to the protein, emulsify it, and immunize mice through multiple subcutaneous injections at the back of the neck, 50μg / mouse; for subsequent immunizations, the adjuvant is replaced with Freund's incomplete adjuvant, and the rest is the same as the first immunization; 7 to 10 days after the third immunization, a small amount of blood is collected from the tail, and the serum titer is determined by indirect ELISA by coating the purified rLP32Δ with 2μg / mL on an enzyme-labeled plate. Mice with a titer higher than 1:4000 are selected for booster immunization three days before fusion, and the protein is directly injected intraperitoneally at a dose of 50μg / mouse. 3 to 5 days after the last immunization, the spleen cells of the mouse with the highest titer are taken for cell fusion.

[0077] 2. Cell fusion and screening of hybridoma cell lines

[0078] Myeloma cells SP2 / 0 with good growth status were chemically fused with the spleen cells of mice with the highest titer detected by ELISA using PEG1450. Positive hybridoma cells were screened by indirect ELISA method with rLP32Δ as coating antigen. After 3 to 5 subclonings by limiting dilution method, a hybridoma cell line 4E2 secreting anti-epidermal dermatosis virus P32 protein was obtained. According to the instructions of IsoQuickTMStrips and Kits for Mouse Monoclonal Isotyping kit, the monoclonal antibody subtype secreted by this hybridoma cell line was G2a.

[0079] 3. Preparation of monoclonal antibodies against P32 protein of leukemia virus

[0080] Healthy multiparous BALB / c mice aged 6 to 8 months were selected and sensitized by intraperitoneal injection of Freund's incomplete adjuvant (0.5 mL / mouse). Hybridoma cells were injected 7 days later. The above three hybridoma cells in logarithmic growth phase and SP2 / 0 cells were collected and centrifuged at 800 r / min for 10 min. The cells were washed once with DMEM culture medium and resuspended to adjust the cell density to 10 6 After the cells were added to each mouse, 0.5 mL was injected into the abdominal cavity of each mouse. The mouse abdomen was gently rubbed with alcohol cotton to evenly disperse the cells in the abdominal cavity. After 7 to 14 days, when the mouse abdomen was obviously swollen, the needle of a 20 ml syringe was aseptically inserted into the swollen part of the mouse abdomen, and gently rubbed and pressed to make the ascites flow out or drip out. The ascites was collected in a 15 ml centrifuge tube, centrifuged at 3000 r / min for 10 min, and marked as 4E2 and ascites control (S) of myeloma cells SP2 / 0, and stored at -20°C for later use.

[0081] Example 3

[0082] Purification and detection of monoclonal ascites

[0083] Protein A (GE Healthcare 17-5079-01) affinity column purification method was used for purification, and the purification steps were as follows:

[0084] Sample pretreatment: dilute the ascites with coupling buffer (20 mM sodium phosphate buffer, pH 7.0) at a ratio of 1:3, centrifuge at 12000 rpm and 4°C for 10 min, and filter with a 0.22 μm filter membrane to remove fat, cell residues and small particles.

[0085] Equilibration: Equilibrate the column with 5 to 10 column volumes of coupling buffer, maintaining a flow rate of 2 s / drop.

[0086] Loading: Use a syringe to inject the sample into the upper interface of the column, collect the effluent in a 50ml centrifuge tube, and maintain a flow rate of 4s / drop.

[0087] Washing: Pass 5 column volumes of coupling buffer through the column, maintaining a flow rate of 2s / drop.

[0088] Elution: Elute the antibody with 5 column volumes of elution buffer (0.1 M sodium citrate buffer, pH 9.0), collect in the above EP tube, and maintain the flow rate at 4 s / drop.

[0089] Sample detection: The purified monoclonal antibody was identified by SDS-PAGE, and a highly pure monoclonal antibody was obtained by purification using a Protein A affinity column; the concentration of the monoclonal antibody was determined using the BCA method, and its concentration could reach 3.2 mg / mL.

[0090] The results of purification of monoclonal antibody 4E2 are as follows Figure 3 shown.

[0091] Example 4

[0092] HRP conjugation of monoclonal antibodies

[0093] Take 0.1 mg of monoclonal antibody 4E2, add 25 μl of activated HRP, mix by pipetting repeatedly 10 times, add 2 μl of coupling catalyst solution to the above mixture of antibody and HRP enzyme, mix by pipetting repeatedly 10 times, let react at room temperature for 2 hours to obtain HRP-labeled 4E2 (HRP-4E2), and divide it into portions for use.

[0094] Example 5

[0095] Development of a blocking ELISA assay for lumpy skin disease virus (LSDV) antibodies based on monoclonal antibody 4E2

[0096] 1. Preparation of anti-LSDV polyclonal antibodies:

[0097] Select cattle as the immunized animal and use 10 5.0 TCID 50 LSDV was injected subcutaneously at multiple points in the abdomen. 14 days after the infection, the serum of the diseased cattle was collected for standby use.

[0098] 2. Determination of the blocking ELISA test conditions for LSDV antibodies

[0099] (1) Optimal working concentrations of bovine anti-LSDV polyclonal and monoclonal antibodies

[0100] The purified rLP32Δ was diluted to 2 μg / ml with PBS, 100 μL / well, blocked overnight at 4°C, washed three times with PBST, and PBST solution containing 5% skim milk powder was added as blocking solution, 200 μL / well, blocked overnight at 4°C;

[0101] The plate was washed three times with PBST solution, and the 96-well ELISA plate was patted dry and stored at -20°C for future use.

[0102] The coated 96-well ELISA plate was taken out from the -20°C refrigerator and placed at room temperature for 30 minutes. The obtained bovine anti-LSDV polyclonal antibody was added. PBS was used as the diluent. The dilutions were 1:20, 1:40 and 1:80, 100 μL / well. Negative serum of corresponding dilutions was added at the same time. The plate was incubated at 37°C for 1 hour.

[0103] Wash three times with PBST solution, add HRP-4E2, use PBS as the diluent, dilute the concentration serially from 2000 times to 16,000 times, 100 μL / well, and incubate at 37°C for 30 minutes.

[0104] The cells were washed three times with PBST solution, and 50 μL / well of soluble TMB substrate colorimetric solution was added. The cells were reacted for 15 min at room temperature in the dark. The reaction was terminated with 2 M H2SO4 solution, and the absorbance was read at 450 nm.

[0105] The OD value of the negative control well is selected to be close to 1.0, and the dilution corresponding to the positive serum blocking rate ≥50% is the optimal working concentration.

[0106] The working dilution of bovine anti-LSDV polyclonal antibody was finally determined to be 1:20, and the working concentration of HRP-4E2 was 1:8000.

[0107] (3) Determination of the criteria for judging the results

[0108] The established antibody blocking ELISA was used to test 60 bovine serum samples, and positive and negative controls were set up to determine the OD 450 , calculate the average And standard deviation (S) = 9.208%. When the sample blocking rate The serum is judged as positive; If the result is between the two, it is considered suspicious and needs to be retested. If it is still suspicious, it is considered positive.

[0109] (4) Specific detection of LSDV antibody blocking ELISA method

[0110] The positive serum of cattle Pasteurellosis antibody, cattle BVDV antibody, and Clostridium perfringens toxin antibody type A and D were diluted 1:20 and tested by ELISA. The results showed that the blocking rates of the above sera were all less than 25.95%, which was negative, indicating no cross reaction, indicating that the method has good specificity.

[0111] (5) Application of LSDV antibody blocking ELISA method

[0112] The detection method provided by the present invention was used to detect 5 sera of cattle infected with LSDV and 30 sera of cattle without LSD symptoms collected clinically. The results showed that the LSDV antibodies in the 5 sera of cattle infected with LSDV were all positive, while the LSDV antibodies in the 30 sera of cattle without LSD symptoms collected clinically were all negative.

[0113] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various changes can be made to the technical scheme of the present invention. These simple variations all belong to the protection scope of the present invention.

[0114] It should also be noted that the various specific technical features and steps described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

[0115] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention. Sequence Listing <110> China Veterinary Drug Administration <120> A monoclonal antibody against nodular dermatosis virus and its application <141> 2022-04-22 <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 756 <212> DNA <213> Artificial Sequence <400> 1 atggcagata ttccattata tgttatacca atcgttggtc gcgaaatttc agatgtagtt 60 ccagaattaa aaagtgataa tgatatattt tataaaaaag tcgacacagt aaaagatttt 120 aaaaattcag atgtaaattt tttttttaaa gataaaaaag atattagttt atcatataag 180 ttccttatat gggaaaaggt agaaaaatca ggaggtgttg aaaattttac agaatatttt 240 tctggattat gtaatgctct ttgtacaaaa gaggcaaaaa gttctattgt taaacacttt 300 agtttatgga aatcgtatgc cgatgcggat ataaaaaatt ctgagaataa gtttattgtt 360 gttaatagag atgatacac gttaaaagat ttataca tacatacat ttaattgaa 420 atgcaagaaa aaaataga cattttccaa tacgtgaaa cttttcataa tagtaattct 480 agaatattgt tcaatcaaga aaataataat tttagttatt cgtacacagg gggatatgat 540 tttaccttat ccgcatatgt aattagatta tcgtctgcca taaaaataat aaacgaaatt 600 aaaaaata aaggtatttc taccagtttta agttttgaaa tgtataagtt ggaaaaagaa 660 ttaaactca atagacaagt ttaatgac tcatctaagt atatactca caatactaag 720 tattgtca aaaaaagaca catcac catcac 756 <210> 2 <211> 252 <212> PRT <213> recombinant p32 of lumpy skin disease virus <400> 2 Met Ala Asp Ile Pro Leu Tyr Val Ile Pro Ile Val Gly Arg Glu Ile 1 5 10 15 Ser Asp Val Val Pro Glu Leu Lys Ser Asp Asn Asp Ile Phe Tyr Lys 20 25 30 Lys Val Asp Thr Val Lys Asp Phe Lys Asn Ser Asp Val Asn Phe Phe 35 40 45 Phe Lys Asp Lys Lys Asp Ile Ser Leu Ser Tyr Lys Phe Leu Ile Trp 50 55 60 Glu Lys Val Glu Lys Ser Gly Gly Val Glu Asn Phe Thr Glu Tyr Phe 65 70 75 80 Ser Gly Leu Cys Asn Ala Leu Cys Thr Lys Glu Ala Lys Ser Ser Ile 85 90 95 Val Lys His Phe Ser Leu Trp Lys Ser Tyr Ala Asp Ala Asp Ile Lys 100 105 110 Asn Ser Glu Asn Lys Phe Ile Val Val Ile Glu Asp Asp Asn Thr Leu 115 120 125 Lys Asp Leu Ile Thr Ile His Asn Ile Ile Ile Glu Met Gln Glu Lys 130 135 140 Asn Ile Asp Ile Phe Gln Leu Arg Glu Thr Phe His Asn Ser Asn Ser 145 150 155 160 Arg Ile Leu Phe Asn Gln Glu Asn Asn Asn Phe Met Tyr Ser Tyr Thr 165 170 175 Gly Gly Tyr Asp Phe Thr Leu Ser Ala Tyr Val Ile Arg Leu Ser Ser 180 185 190 Ala Ile Lys Ile Ile Asn Glu Ile Ile Lys Asn Lys Gly Ile Ser Thr 195 200 205 Ser Leu Ser Phe Glu Met Tyr Lys Leu Glu Lys Glu Leu Lys Leu Asn 210 215 220 Arg Gln Val Leu Asn Asp Ser Ser Lys Tyr Ile Leu His Asn Thr Lys 225 230 235 240 Tyr Leu Ser Light Light Arg His His His His His His 245 250

Claims

1. An immunogenic protein rLP32Δ, Features: The encoding nucleotide sequence of the protein rLP32Δ is shown in positions 4 to 717 of SEQ ID No.1, which is obtained by optimizing the amino acid coding sequence at positions 1 to 238 of the P32 protein of the nodular dermatosis virus according to the preferred codons of Escherichia coli, introducing a 6×His tag at the C-terminus, and synthesizing the gene fragment GLP32Δ; the amino acid sequence of the protein rLP32Δ is shown in positions 2 to 239 of SEQ ID No.2, which is prepared using the BL21 (DE3) cell strain of the host cell Escherichia coli that recombinantly expresses rLP32Δ as a production strain, and the production strain is the Escherichia coli BL / 321 strain, with the accession number of CGMCC No.24528.

2. A hybridoma cell line secreting monoclonal antibodies against dermatophytosis virus, It is characterized in that The hybridoma cell strain is Escherichia coli BL / 321 strain, and its deposit number is CGMCC No.24528.

3. A use of a monoclonal antibody against lumpy skin disease virus for preparing a medicament, a reagent, a test plate or a kit; the reagent, the test plate or the kit is used to detect lumpy skin disease virus in a sample; the medicament is used for screening animals that are antibody-negative for lumpy skin disease virus and / or for testing vaccine efficacy, and the monoclonal antibody against lumpy skin disease virus is obtained by secretion from the hybridoma cell line of the monoclonal antibody against lumpy skin disease virus as described in claim 2.

Citation Information

Patent Citations

  • Antibody for resisting lumpy skin disease, test paper and kit

    CN112111006A

  • Monoclonal antibody for resisting porcine epidemic diarrhea virus nsp13 protein and application

    CN112175086A

  • Elisa test system for segological diagnostics of cattle nodulous dermatitis - dermatitis nodularis bovum

    RU2640192C1

  • General monoclonal antibody for african swine fever virus strains as well as preparation method therefor and application thereof

    WO2016086554A1